Aarhus University Seal / Aarhus Universitets segl

Anders Hammerich Riis

Pre-admission use of glucocorticoids and 30-day mortality following colorectal cancer surgery: a population-based Danish cohort study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Pre-admission use of glucocorticoids and 30-day mortality following colorectal cancer surgery : a population-based Danish cohort study. / Ostenfeld, E B; Erichsen, R; Thorlacius-Ussing, O; Riis, A H; Sørensen, H T.

In: Alimentary Pharmacology and Therapeutics, Vol. 39, No. 8, 04.2014, p. 843-53.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{e98bb5fb500c4b98baf550de7d9abea4,
title = "Pre-admission use of glucocorticoids and 30-day mortality following colorectal cancer surgery: a population-based Danish cohort study",
abstract = "BACKGROUND: Previous studies indicate that pre-admission glucocorticoids increase the risk of perioperative complications.AIM: To examine whether pre-admission use of glucocorticoids affects 30-day mortality after colorectal cancer (CRC) surgery.METHODS: We conducted a nationwide population-based cohort study by linking Danish medical registries. All residents in Denmark who underwent CRC surgery from 2001 to 2011 were included. We characterised subjects who filled their most recent glucocorticoid prescription ≤90, 91-365 and >365 days before their surgery date as prevalent, recent and former users, respectively. Prevalent users were subgrouped into new (first-ever prescription ≤90 days before surgery date) and continuing users. We estimated 30-day cumulative mortality by the Kaplan-Meier method and corresponding mortality rate ratios (MRRs) using Cox proportional hazard regression, adjusting for potential confounders.RESULTS: Of the 34 641 CRC patients included, 3966 (11.5%) had filled one or more prescriptions of glucocorticoids within the year before the surgery date. Thirty-day mortality among prevalent users of oral glucocorticoids was 15.0% vs. 7.3% among non-users [MRR = 1.28; 95% confidence interval (CI): 1.03, 1.58]. Among new users, the 30-day mortality was 17.8% (MRR = 1.92; 95% CI: 1.30, 2.83) while it was 14.2% among continuing users (MRR = 1.13; 95% CI: 0.88, 1.44). No associations were found for recent or former use of oral glucocorticoids nor for use of inhaled, intestinal-acting, and mixed glucocorticoids.CONCLUSIONS: Prevalent use, particulary new use, of oral glucocorticoids was associated with markedly increased 30-day mortality after colorectal cancer surgery compared to patients not exposed to any glucocorticoids.",
keywords = "Administration, Oral, Aged, Aged, 80 and over, Cohort Studies, Colorectal Neoplasms, Confidence Intervals, Denmark, Female, Glucocorticoids, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Prevalence, Proportional Hazards Models, Registries, Time Factors",
author = "Ostenfeld, {E B} and R Erichsen and O Thorlacius-Ussing and Riis, {A H} and S{\o}rensen, {H T}",
note = "{\textcopyright} 2014 John Wiley & Sons Ltd.",
year = "2014",
month = apr,
doi = "10.1111/apt.12667",
language = "English",
volume = "39",
pages = "843--53",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd.",
number = "8",

}

RIS

TY - JOUR

T1 - Pre-admission use of glucocorticoids and 30-day mortality following colorectal cancer surgery

T2 - a population-based Danish cohort study

AU - Ostenfeld, E B

AU - Erichsen, R

AU - Thorlacius-Ussing, O

AU - Riis, A H

AU - Sørensen, H T

N1 - © 2014 John Wiley & Sons Ltd.

PY - 2014/4

Y1 - 2014/4

N2 - BACKGROUND: Previous studies indicate that pre-admission glucocorticoids increase the risk of perioperative complications.AIM: To examine whether pre-admission use of glucocorticoids affects 30-day mortality after colorectal cancer (CRC) surgery.METHODS: We conducted a nationwide population-based cohort study by linking Danish medical registries. All residents in Denmark who underwent CRC surgery from 2001 to 2011 were included. We characterised subjects who filled their most recent glucocorticoid prescription ≤90, 91-365 and >365 days before their surgery date as prevalent, recent and former users, respectively. Prevalent users were subgrouped into new (first-ever prescription ≤90 days before surgery date) and continuing users. We estimated 30-day cumulative mortality by the Kaplan-Meier method and corresponding mortality rate ratios (MRRs) using Cox proportional hazard regression, adjusting for potential confounders.RESULTS: Of the 34 641 CRC patients included, 3966 (11.5%) had filled one or more prescriptions of glucocorticoids within the year before the surgery date. Thirty-day mortality among prevalent users of oral glucocorticoids was 15.0% vs. 7.3% among non-users [MRR = 1.28; 95% confidence interval (CI): 1.03, 1.58]. Among new users, the 30-day mortality was 17.8% (MRR = 1.92; 95% CI: 1.30, 2.83) while it was 14.2% among continuing users (MRR = 1.13; 95% CI: 0.88, 1.44). No associations were found for recent or former use of oral glucocorticoids nor for use of inhaled, intestinal-acting, and mixed glucocorticoids.CONCLUSIONS: Prevalent use, particulary new use, of oral glucocorticoids was associated with markedly increased 30-day mortality after colorectal cancer surgery compared to patients not exposed to any glucocorticoids.

AB - BACKGROUND: Previous studies indicate that pre-admission glucocorticoids increase the risk of perioperative complications.AIM: To examine whether pre-admission use of glucocorticoids affects 30-day mortality after colorectal cancer (CRC) surgery.METHODS: We conducted a nationwide population-based cohort study by linking Danish medical registries. All residents in Denmark who underwent CRC surgery from 2001 to 2011 were included. We characterised subjects who filled their most recent glucocorticoid prescription ≤90, 91-365 and >365 days before their surgery date as prevalent, recent and former users, respectively. Prevalent users were subgrouped into new (first-ever prescription ≤90 days before surgery date) and continuing users. We estimated 30-day cumulative mortality by the Kaplan-Meier method and corresponding mortality rate ratios (MRRs) using Cox proportional hazard regression, adjusting for potential confounders.RESULTS: Of the 34 641 CRC patients included, 3966 (11.5%) had filled one or more prescriptions of glucocorticoids within the year before the surgery date. Thirty-day mortality among prevalent users of oral glucocorticoids was 15.0% vs. 7.3% among non-users [MRR = 1.28; 95% confidence interval (CI): 1.03, 1.58]. Among new users, the 30-day mortality was 17.8% (MRR = 1.92; 95% CI: 1.30, 2.83) while it was 14.2% among continuing users (MRR = 1.13; 95% CI: 0.88, 1.44). No associations were found for recent or former use of oral glucocorticoids nor for use of inhaled, intestinal-acting, and mixed glucocorticoids.CONCLUSIONS: Prevalent use, particulary new use, of oral glucocorticoids was associated with markedly increased 30-day mortality after colorectal cancer surgery compared to patients not exposed to any glucocorticoids.

KW - Administration, Oral

KW - Aged

KW - Aged, 80 and over

KW - Cohort Studies

KW - Colorectal Neoplasms

KW - Confidence Intervals

KW - Denmark

KW - Female

KW - Glucocorticoids

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Prevalence

KW - Proportional Hazards Models

KW - Registries

KW - Time Factors

U2 - 10.1111/apt.12667

DO - 10.1111/apt.12667

M3 - Journal article

C2 - 24611938

VL - 39

SP - 843

EP - 853

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 8

ER -